Ali DÜZOVA, Berna OĞUZ, Duygu Övünç HACIHAMDİOĞLU, Nesrin BEŞBAŞ, Dursun ALEHAN

Circulating fibroblast growth factor 23 in children on peritoneal dialysis is associated with effective dialysis

Hacıhamdioğlu DÖ, Düzova A, Alehan D, Oğuz B, Beşbaş N. Circulating fibroblast growth factor 23 in children on peritoneal dialysis is associated with effective dialysis. Turk J Pediatr 2015; 57: 9-16.Our purpose was to assess the relationship between serum fibroblast growth factor 23 (FGF23) and left ventricular function, carotid intima-media thickness (CIMT) and laboratory features in children on peritoneal dialysis (PD). The study population consisted of 17 patients (11 female; median age 7.83 years, range 0.66-17.75) undergoing PD for 22 months . Serum FGF23, serum phosphorus, calcium, intact parathyroid hormone (iPTH), 25(OH) vitamin D, 1,25(OH)2 vitamin D and Kt/V urea, left ventricular mass (LVM) and LVM index (LVMI) were assessed. Median FGF23 level was 29.92 pg/ml (22.7-74.76), phosphorus was 5.2 mg/dl (3.1-9.9), iPTH was 438 pg/ml , 25(OH) vitamin D was 11 ng/ml , 1,25(OH)2 vitamin D was 11 pg/ml , Kt/V urea was 2.33 (1.013.84). FGF23 level was independently associated with Kt/V urea (p

PDF

___

Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
Ma KW, Greene EL, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19: 505-513.
Meisinger C, Döring A, Löwel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 2006, 27: 1245-1250.
Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291: E38-E49.
Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009; 45: 1161-1168.
Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561–568.
Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545- 2552.
Yilmaz MI, Sonmez A, Saglam M, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78: 679-685.
Balci M, Kirkpantur A, Gulbay M, Gurbuz OA. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int 2010; 14: 425-432.
Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43: 572-579.
Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol 2012; 27: 2129-2136.
Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011; 26: 945-951.
CDC Growth Charts: Percentile Data Files with LMS Values. http://www.cdc.gov/growthcharts/percentile_ data_files.htm. [The last entry was made in March 2014.]
Nolph KD, Moore HL, Twardowski ZJ, et al. Cross- sectional assessment of weekly urea and creatinine clearances in patients on continuous ambulatory peritoneal dialysis. ASAIO J 1992; 38: M139-M142.
Tzamaloukas AH, Murata GH, Sena P. Assessing the adequacy of peritoneal dialysis. Perit Dial Int 1993; 13: 236-238.
Lai WW, Geva T, Shirali GS, et al. Guidelines and standards for performance of a pediatric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography. J Am Soc Echocardiogr 2006; 19:1413-1430.
Rogé CL, Silverman NH, Hart PA, Ray RM. Cardiac structure growth pattern determined by echocardiography. Circulation 1978; 57: 285-290.
Foster BJ, Mackie AS, Mitsnefes M, Ali H, Mamber S, Colan SD. A novel method of expressing left ventricular mass relative to body size in children. Circulation 2008; 117: 2769-2775.
Borzych D, Bakkaloglu SA, Zaritsky J, et al. Defining left ventricular hypertrophy in children on peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6: 1934-1943.
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555–576.
Doyon A, Kracht D, Bayazit AK, et al. Carotid artery intima-media thickness and distensibility in children and adolescents: reference values and role of body dimensions. Hypertension 2013; 62: 550-556.
KDOQI Work Group. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009; 53: S11-S104.
van Husen M, Fischer AK, Lehnhardt A, et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010; 78: 200-206.
Wesseling-Perry K, Pereira RC, Wang H, et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94: 511-517.
Ceballos OML, Rojo LA, Azócar PM, et al. [Mineral metabolism in patients on chronic peritoneal dialysis]. [Article in Spanish] Rev Chil Pediatr 2014; 85: 31-39.
Isakova T, Xie H, Barchi-Chung A, et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6: 2688-2695.
Yamada S, Tsuruya K, Taniguchi M, et al. Relationship between residual renal function and serum fibroblast growth factor 23 in patients on peritoneal dialysis. Ther Apher Dial 2014; 18: 383-390.
Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
Knap B, Večerić-Haler Ž, Benedik M, Buturović-Ponikvar J, Ponikvar R, Bren AF. Fibroblast growth factor 23 and left ventricular mass index in maintenance hemodialysis patients: standard versus long nocturnal hemodialysis. Ther Apher Dial 2013; 17: 407-411.
Kalkwarf HJ, Denburg MR, Strife CF, et al. Vitamin D deficiency is common in children and adolescents with chronic kidney disease. Kidney Int 2012; 81: 690-697.
Jacob AI, Sallman A, Santiz Z, Hollis BW. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr 1984; 114: 1313–1319.
Bosworth CR, Levin G, Robinson-Cohen C, et al. The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int 2012; 82: 693-700.
Denburg MR, Kalkwarf HJ, Boer IH, et al. Vitamin D bioavailability and catabolism in pediatric chronic kidney disease. Pediatr Nephrol 2013; 28: 1843-1853.
Inaba M, Okuno S, Imanishi Y, et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006; 17: 1506-1513.
Asicioglu E, Kahveci A, Arikan H, Koc M, Tuglular S, Ozener C. Fibroblast growth factor-23 levels are associated with uric acid but not carotid intima media thickness in renal transplant recipients. Transplant Proc 2014; 46: 180-183.